血浆分馏市场:趋势，机会及竞争分析(2023年～2028年)

全球血浆分馏的市场规模，预计2023年至2028年以7％的年复合成长率扩大，至2028年达到427亿美元。这个市场的主要促进因素，是老年人口增加，呼吸疾病盛行率的上升，各种治疗用途的免疫球蛋白的使用增加。

本报告提供全球血浆分馏市场相关调查，市场概要，以及各产品，各手法，各用途，各最终用途产业，各地区趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 摘要整理

第2章 全球血浆分馏市场:市场动态

第3章 市场趋势与预测分析，2017年～2028年

• 宏观经济趋势(2017年～2022年)与预测(2023年～2028年)
• 全球血浆分馏市场趋势(2017年～2022年)与预测(2023年～2028年)
• 全球血浆分馏市场，各产品
  • 白蛋白
  • 免疫球蛋白
  • 凝血因子
  • 蛋白分解酵素抑制剂
  • 其他
• 全球血浆分馏市场，各手法
  • 离心分离
  • 深层过滤
  • 层析法
  • 其他
• 全球血浆分馏市场，各用途
  • 神经学
  • 血液学
  • 肿瘤学
  • 免疫学
  • 呼吸系统医疗设备
  • 其他
• 全球血浆分馏市场，各最终用途产业
  • 医院、诊疗所
  • 临床研究
  • 其他

第4章 市场趋势与预测分析，各地区，2017年～2028年

• 全球血浆分馏市场，各地区
• 北美的血浆分馏市场
• 欧洲的血浆分馏市场
• 亚太地区的血浆分馏市场
• 其他地区的血浆分馏市场

第5章 竞争的分析

第6章 成长机会及策略分析

• 成长机会分析
• 全球血浆分馏市场上新的趋势
• 策略分析

第7章 主要加入企业的企业简介

• Grifols
• CSL
• Takeda Pharmaceutical
• Octapharma
• Kedrion

Plasma Fractionation Market Trends and Forecast

The future of the plasma fractionation market looks promising with opportunities in hospitals & clinics and clinical research. The global plasma fractionation market is expected to reach an estimated $42.7 billion by 2028 with a CAGR of 7% from 2023 to 2028. The major drivers for this market are rising geriatric population, increasing prevalence of respiratory diseases, and growing use of immunoglobulin in different therapeutic applications.

Plasma Fractionation Market by Product, Method, Application, End Use Industry, and Region

A more than 150-page report is developed to help in your business decisions. A sample figure with some insights is shown below.

Plasma Fractionation Market by Segments

Plasma Fractionation Market by Segment

The study includes trends and forecast for the global plasma fractionation market by product, method, application, end use industry, and region, as follows:

Plasma Fractionation Market by Product [Value ($B) Shipment Analysis from 2017 to 2028]:

Albumin

Immunoglobulins

Intravenous immunoglobulins

Subcutaneous immunoglobulins

Others

Coagulation Factors

Factor VIII

Factor IX

Von Willebrand Factor

Prothrombin Complex Concentrates

Fibrinogen Concentrates

Others

Protease Inhibitors

Others

Plasma Fractionation Market by Method [Value ($B) Shipment Analysis from 2017 to 2028]:

Centrifugation

Depth Filtration

Chromatography

Others

Plasma Fractionation Market by Application [Value ($B) Shipment Analysis from 2017 to 2028]:

Neurology

Hematology

Oncology

Immunology

Pulmonology

Others

Plasma Fractionation Market by End Use Industry [Value ($B) Shipment Analysis from 2017 to 2028]:

Hospitals & Clinics

Clinical Research

Others

Plasma Fractionation Market by Region [Value ($B) Shipment Analysis from 2017 to 2028]:

North America

Europe

Asia Pacific

The Rest of the World

List of Plasma Fractionation Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, plasma fractionation companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the plasma fractionation companies profiled in this report include-

Grifols

CSL

Takeda Pharmaceutical

Octapharma

Kedrion

Plasma Fractionation Market Insights

Lucintel forecasts that immunoglobulin will remain the largest product segment over the forecast period due to the increasing prevalence of infections and disorders and its extensive use in treatment, diagnosis, and administration of metabolic diseases.

Hospitals & clinics are expected to remain the largest end use industry segment due to the extensive use of plasma fractionation among hospitals and clinics to treat various diseases.

North America will remain the largest region due to an increase in the quantity of plasma collection facilities, rise in the demand for immunoglobulin, and growing number of elderly people with hereditary diseases in the region.

Features of the Plasma Fractionation Market

Market Size Estimates: Plasma fractionation market size estimation in terms of value ($B)

Trend And Forecast Analysis: Market trends (2017-2022) and forecast (2023-2028) by various segments and regions.

Segmentation Analysis: Plasma fractionation market size by various segments, such as product, method, application, end use industry, and region

Regional Analysis: Plasma fractionation market breakdown by North America, Europe, Asia Pacific, and the Rest of the World.

Growth Opportunities: Analysis on growth opportunities in different products, methods, applications, end use industries, and regions for the plasma fractionation market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape for the plasma fractionation market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the plasma fractionation market size?

Answer: The global plasma fractionation market is expected to reach an estimated $42.7 billion by 2028.

Q2. What is the growth forecast for plasma fractionation market?

Answer: The global plasma fractionation market is expected to grow with a CAGR of 7% from 2023 to 2028.

Q3. What are the major drivers influencing the growth of the plasma fractionation market?

Answer: The major drivers for this market are rising geriatric population, increasing prevalence of respiratory diseases, and growing use of immunoglobulin in different therapeutic applications.

Q4. What are the major segments for plasma fractionation market?

Answer: The future of the plasma fractionation market looks promising with opportunities in hospitals & clinics and clinical research.

Q5. Who are the key plasma fractionation companies?

Answer: Some of the key plasma fractionation companies are as follows:

Grifols

CSL

Takeda Pharmaceutical

Octapharma

Kedrion

Q6. Which plasma fractionation segment will be the largest in the future?

Answer: Lucintel forecasts that immunoglobulin will remain the largest product segment over the forecast period due to the increasing prevalence of infections and disorders and its extensive use for the treatment, diagnosis, and administration of metabolic diseases.

Q7. In plasma fractionation market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region due to increase in quantity of plasma collection facilities, rise in the demand for immunoglobulin, and growing number of elderly people with hereditary diseases in the region.

Q8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% Customization Without any Additional Cost.

This report answers following 11 key questions

• Q.1. What are some of the most promising, high-growth opportunities for the plasma fractionation market by product (albumin, immunoglobulins, coagulation factors, protease inhibitors, and others), method (centrifugation, depth filtration, chromatography, and others), application (neurology, hematology, oncology, immunology, pulmonology, and others), end use industry (hospitals & clinics, clinical research, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Plasma Fractionation Market: Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2017 to 2028

• 3.1: Macroeconomic Trends (2017-2022) and Forecast (2023-2028)
• 3.2: Global Plasma Fractionation Market Trends (2017-2022) and Forecast (2023-2028)
• 3.3: Global Plasma Fractionation Market by Product
  • 3.3.1: Albumin
  • 3.3.2: Immunoglobulins
    • 3.3.2.1: Intravenous immunoglobulins
    • 3.3.2.2: Subcutaneous immunoglobulins
    • 3.3.2.3: Others
  • 3.3.3: Coagulation Factors
    • 3.3.3.1: Factor VIII
    • 3.3.3.2: Factor IX
    • 3.3.3.3: Von Willebrand Factor
    • 3.3.3.4: Prothrombin Complex Concentrates
    • 3.3.3.5: Fibrinogen Concentrates
    • 3.3.3.6: Others
  • 3.3.4: Protease Inhibitors
  • 3.3.5: Others
• 3.4: Global Plasma Fractionation Market by Method
  • 3.4.1: Centrifugation
  • 3.4.2: Depth Filtration
  • 3.4.3: Chromatography
  • 3.4.4: Others
• 3.5: Global Plasma Fractionation Market by Application
  • 3.5.1: Neurology
  • 3.5.2: Hematology
  • 3.5.3: Oncology
  • 3.5.4: Immunology
  • 3.5.5: Pulmonology
  • 3.5.6: Others
• 3.6: Global Plasma Fractionation Market by End Use Industry
  • 3.6.1: Hospitals & Clinics
  • 3.6.2: Clinical Research
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2017 to 2028

• 4.1: Global Plasma Fractionation Market by Region
• 4.2: North American Plasma Fractionation Market
  • 4.2.1: North American Plasma Fractionation Market by Product: Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, and Others
  • 4.2.2: North American Plasma Fractionation Market by End Use Industry: Hospitals & Clinics, Clinical Research, and Others
• 4.3: European Plasma Fractionation Market
  • 4.3.1: European Plasma Fractionation Market by Product: Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, and Others
  • 4.3.2: European Plasma Fractionation Market by End Use Industry: Hospitals & Clinics, Clinical Research, and Others
• 4.4: APAC Plasma Fractionation Market
  • 4.4.1: APAC Plasma Fractionation Market by Product: Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, and Others
  • 4.4.2: APAC Plasma Fractionation Market by End Use Industry: Hospitals & Clinics, Clinical Research, and Others
• 4.5: ROW Plasma Fractionation Market
  • 4.5.1: ROW Plasma Fractionation Market by Product: Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, and Others
  • 4.5.2: ROW Plasma Fractionation Market by End Use Industry: Hospitals & Clinics, Clinical Research, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Plasma Fractionation Market by Product
  • 6.1.2: Growth Opportunities for the Global Plasma Fractionation Market by Method
  • 6.1.3: Growth Opportunities for the Global Plasma Fractionation Market by Application
  • 6.1.4: Growth Opportunities for the Global Plasma Fractionation Market by End Use Industry
  • 6.1.5: Growth Opportunities for the Global Plasma Fractionation Market by Region
• 6.2: Emerging Trends in the Global Plasma Fractionation Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Plasma Fractionation Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Plasma Fractionation Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Grifols
• 7.2: CSL
• 7.3: Takeda Pharmaceutical
• 7.4: Octapharma
• 7.5: Kedrion